{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:16:33Z","timestamp":1785435393479,"version":"3.56.0"},"reference-count":8,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.<\/jats:p>","DOI":"10.7554\/elife.103775","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T10:45:10Z","timestamp":1730889910000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.103775","source":"Crossref","is-referenced-by-count":0,"title":["Predicting drug resistance"],"prefix":"10.7554","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-0467","authenticated-orcid":true,"given":"Nicole S","family":"Arellano","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine and the Division of Hematology and Hematologic Malignancies, University of Utah","place":["Salt Lake City, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-3818","authenticated-orcid":true,"given":"Shannon E","family":"Elf","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine and the Division of Hematology and Hematologic Malignancies, University of Utah","place":["Salt Lake City, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nature Medicine"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"NEJM"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer heterogeneity: implications for targeted therapeutics","volume":"108","author":"Fisher","year":"2013","journal-title":"British Journal of Cancer"},{"key":"bib5","first-page":"62","article-title":"New hope for cancer","volume":"157","author":"Lemonick","year":"2001","journal-title":"Time"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"bib7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.92074","article-title":"Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response","volume":"12","author":"Warfvinge","year":"2023","journal-title":"eLife"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.exphem.2016.08.010","article-title":"Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity","volume":"44","author":"Yanagisawa","year":"2016","journal-title":"Experimental Hematology"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/103775\/elife-103775-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/103775\/elife-103775-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/103775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T10:45:46Z","timestamp":1730889946000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/103775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":8,"alternative-id":["10.7554\/eLife.103775"],"URL":"https:\/\/doi.org\/10.7554\/elife.103775","archive":["CLOCKSS"],"relation":{},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"article-number":"e103775"}}